Table 1 Baseline characteristics of EV positive patients
Clinical parameters | EV persistence (n = 23) | EV clearance (n = 42) | EV persistence + IFN-β (n = 32) | ANOVA p value |
|---|---|---|---|---|
Age (years ± SD) | 54 ± 14 | 47 ± 15 | 50 ± 13 | 0.198 |
Male [n (%)] | 18 (78.3) | 26 (66.7) | 22 (62.9) | 0.379 |
NYHA I/II/III/IV (%) | 8.3/66.7/16.6/8.3 | 16.0/56.0/24.0/4.0 | 4.2/54.2/37.5/4.2 | 0.451 |
EF at baseline (% ± SD) | 45 ± 19 | 52 ± 18 | 51 ± 19 | 0.293 |
Endpoint of death [n (%)] | 11 (47.8) | 4 (9.5) | 0 (0) | 0.001 |
LVEDD (mm ± SD) | 59 ± 10 | 54 ± 11 | 58 ± 7 | 0.121 |
LVEDS (mm ± SD) | 46 ± 13 | 42 ± 12 | 41 ± 11 | 0.467 |
Palpitations (%) | 27.8 | 54.3 | 34.6 | 0.122 |
Arrhythmias (%) | 26.7 | 46.7 | 25.0 | 0.219 |
AVB (%) | 11.1 | 6.7 | 8.3 | 0.870 |
RBBB (%) | 11.1 | 9.7 | 4.2 | 0.677 |
LBBB (%) | 11.8 | 22.6 | 8.7 | 0.346 |
Syncopies (%) | 23.5 | 11.4 | 3.8 | 0.146 |
Diabetes (%) | 11.1 | 18.4 | 19.2 | 0.635 |
Glycosides (%) | 30.0 | 12.5 | 40.7 | 0.061 |
Diuretics (%) | 42.9 | 59.1 | 70.0 | 0.297 |
Β-blocker (%) | 43.8 | 21.9 | 57.7 | 0.686 |
ACE (%) | 70.6 | 56.7 | 70.8 | 0.483 |
Cumarin (%) | 25.0 | 12.9 | 29.6 | 0.292 |
Antiarrhythmics (%) | 30.8 | 13.6 | 15.8 | 0.435 |
Pacemaker/ICD (%) | 10/10 | 0/2.8 | 0/5.8 | 0.146 |